TG Therapeutics Inc. (TGTX) is drawing attention after releasing preliminary fourth-quarter and full-year 2025 results, along with 2026 financial guidance and a robust development pipeline update at the 44th Annual J.P. Morgan Healthcare Conference.
The company's BRIUMVI (ublituximab-xiiy) continues to deliver strong commercial performance, positioning TG Therapeutics for sustained growth in the multiple sclerosis (MS) market and beyond.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com